123 related articles for article (PubMed ID: 35772287)
1. Structure-activity relationships of 2-pyrimidinecarbohydrazides as utrophin modulators for the potential treatment of Duchenne muscular dystrophy.
Chatzopoulou M; Conole D; Emer E; Rowley JA; Willis NJ; Squire SE; Gill B; Brough S; Wilson FX; Wynne GM; Davies SG; Davies KE; Russell AJ
Bioorg Med Chem; 2022 Sep; 69():116812. PubMed ID: 35772287
[TBL] [Abstract][Full Text] [Related]
2. Discovery and mechanism of action studies of 4,6-diphenylpyrimidine-2-carbohydrazides as utrophin modulators for the treatment of Duchenne muscular dystrophy.
Vuorinen A; Wilkinson IVL; Chatzopoulou M; Edwards B; Squire SE; Fairclough RJ; Bazan NA; Milner JA; Conole D; Donald JR; Shah N; Willis NJ; Martínez RF; Wilson FX; Wynne GM; Davies SG; Davies KE; Russell AJ
Eur J Med Chem; 2021 Aug; 220():113431. PubMed ID: 33915371
[TBL] [Abstract][Full Text] [Related]
3. 2-Arylbenzo[
Babbs A; Berg A; Chatzopoulou M; Davies KE; Davies SG; Edwards B; Elsey DJ; Emer E; Guiraud S; Harriman S; Lecci C; Moir L; Peters D; Robinson N; Rowley JA; Russell AJ; Squire SE; Tinsley JM; Wilson FX; Wynne GM
J Med Chem; 2020 Jul; 63(14):7880-7891. PubMed ID: 32551645
[TBL] [Abstract][Full Text] [Related]
4. Chemical Proteomics and Phenotypic Profiling Identifies the Aryl Hydrocarbon Receptor as a Molecular Target of the Utrophin Modulator Ezutromid.
Wilkinson IVL; Perkins KJ; Dugdale H; Moir L; Vuorinen A; Chatzopoulou M; Squire SE; Monecke S; Lomow A; Geese M; Charles PD; Burch P; Tinsley JM; Wynne GM; Davies SG; Wilson FX; Rastinejad F; Mohammed S; Davies KE; Russell AJ
Angew Chem Int Ed Engl; 2020 Feb; 59(6):2420-2428. PubMed ID: 31755636
[TBL] [Abstract][Full Text] [Related]
5. Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies.
Soblechero-Martín P; López-Martínez A; de la Puente-Ovejero L; Vallejo-Illarramendi A; Arechavala-Gomeza V
Neuropathol Appl Neurobiol; 2021 Oct; 47(6):711-723. PubMed ID: 33999469
[TBL] [Abstract][Full Text] [Related]
6. Alternative utrophin mRNAs contribute to phenotypic differences between dystrophin-deficient mice and Duchenne muscular dystrophy.
Perkins KJ; Davies KE
FEBS Lett; 2018 Jun; 592(11):1856-1869. PubMed ID: 29772070
[TBL] [Abstract][Full Text] [Related]
7. Identifying FDA-Approved Drugs that Upregulate Utrophin A as a Therapeutic Strategy for Duchenne Muscular Dystrophy.
Péladeau C; Jasmin BJ
Methods Mol Biol; 2023; 2587():495-510. PubMed ID: 36401046
[TBL] [Abstract][Full Text] [Related]
8. Utrophin upregulation in Duchenne muscular dystrophy.
Hirst RC; McCullagh KJ; Davies KE
Acta Myol; 2005 Dec; 24(3):209-16. PubMed ID: 16629055
[TBL] [Abstract][Full Text] [Related]
9. A Phase 1b Trial to Assess the Pharmacokinetics of Ezutromid in Pediatric Duchenne Muscular Dystrophy Patients on a Balanced Diet.
Muntoni F; Tejura B; Spinty S; Roper H; Hughes I; Layton G; Davies KE; Harriman S; Tinsley J
Clin Pharmacol Drug Dev; 2019 Oct; 8(7):922-933. PubMed ID: 30650257
[TBL] [Abstract][Full Text] [Related]
10. Isolation, Structural Identification, Synthesis, and Pharmacological Profiling of 1,2-
Chatzopoulou M; Claridge TDW; Davies KE; Davies SG; Elsey DJ; Emer E; Fletcher AM; Harriman S; Robinson N; Rowley JA; Russell AJ; Tinsley JM; Weaver R; Wilkinson IVL; Willis NJ; Wilson FX; Wynne GM
J Med Chem; 2020 Mar; 63(5):2547-2556. PubMed ID: 31599580
[TBL] [Abstract][Full Text] [Related]
11. Correlation of Utrophin Levels with the Dystrophin Protein Complex and Muscle Fibre Regeneration in Duchenne and Becker Muscular Dystrophy Muscle Biopsies.
Janghra N; Morgan JE; Sewry CA; Wilson FX; Davies KE; Muntoni F; Tinsley J
PLoS One; 2016; 11(3):e0150818. PubMed ID: 26974331
[TBL] [Abstract][Full Text] [Related]
12. Embryonic myosin is a regeneration marker to monitor utrophin-based therapies for DMD.
Guiraud S; Edwards B; Squire SE; Moir L; Berg A; Babbs A; Ramadan N; Wood MJ; Davies KE
Hum Mol Genet; 2019 Jan; 28(2):307-319. PubMed ID: 30304405
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Quinazoline and Quinoline-Based Small Molecules as Utrophin Upregulators via AhR Antagonism for the Treatment of Duchenne Muscular Dystrophy.
Ghosh S; Arshi MU; Ghosh S; Jash M; Sen S; Mamchaoui K; Bhattacharyya S; Rana NK; Ghosh S
J Med Chem; 2024 Jun; 67(11):9260-9276. PubMed ID: 38771158
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 2-arylbenzoxazoles as upregulators of utrophin production for the treatment of Duchenne muscular dystrophy.
Chancellor DR; Davies KE; De Moor O; Dorgan CR; Johnson PD; Lambert AG; Lawrence D; Lecci C; Maillol C; Middleton PJ; Nugent G; Poignant SD; Potter AC; Price PD; Pye RJ; Storer R; Tinsley JM; van Well R; Vickers R; Vile J; Wilkes FJ; Wilson FX; Wren SP; Wynne GM
J Med Chem; 2011 May; 54(9):3241-50. PubMed ID: 21456623
[TBL] [Abstract][Full Text] [Related]
15. Sarcospan integration into laminin-binding adhesion complexes that ameliorate muscular dystrophy requires utrophin and α7 integrin.
Marshall JL; Oh J; Chou E; Lee JA; Holmberg J; Burkin DJ; Crosbie-Watson RH
Hum Mol Genet; 2015 Apr; 24(7):2011-22. PubMed ID: 25504048
[TBL] [Abstract][Full Text] [Related]
16. Naturally occurring utrophin correlates with disease severity in Duchenne muscular dystrophy.
Kleopa KA; Drousiotou A; Mavrikiou E; Ormiston A; Kyriakides T
Hum Mol Genet; 2006 May; 15(10):1623-8. PubMed ID: 16595608
[TBL] [Abstract][Full Text] [Related]
17. Metabolic remodeling of dystrophic skeletal muscle reveals biological roles for dystrophin and utrophin in adaptation and plasticity.
Hardee JP; Martins KJB; Miotto PM; Ryall JG; Gehrig SM; Reljic B; Naim T; Chung JD; Trieu J; Swiderski K; Philp AM; Philp A; Watt MJ; Stroud DA; Koopman R; Steinberg GR; Lynch GS
Mol Metab; 2021 Mar; 45():101157. PubMed ID: 33359740
[TBL] [Abstract][Full Text] [Related]
18. The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy.
Guiraud S; Edwards B; Babbs A; Squire SE; Berg A; Moir L; Wood MJ; Davies KE
Hum Mol Genet; 2019 Jul; 28(13):2189-2200. PubMed ID: 30990876
[TBL] [Abstract][Full Text] [Related]
19. Celecoxib treatment improves muscle function in mdx mice and increases utrophin A expression.
Péladeau C; Adam NJ; Jasmin BJ
FASEB J; 2018 Sep; 32(9):5090-5103. PubMed ID: 29723037
[TBL] [Abstract][Full Text] [Related]
20. PMO-based let-7c site blocking oligonucleotide (SBO) mediated utrophin upregulation in mdx mice, a therapeutic approach for Duchenne muscular dystrophy (DMD).
Sengupta K; Loro E; Khurana TS
Sci Rep; 2020 Dec; 10(1):21492. PubMed ID: 33298994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
